Article
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Cancer research communications - 1 Jul 2024
Maldonado Edward, Rathmell W Kimryn, Shapiro Geoffrey I, Takebe Naoko, Rodon Jordi, Mahalingam Devalingam, Trikalinos Nikolaos A, Kalebasty Arash R, Parikh Mamta, Boerner Scott A, Balido Celene, Krings Gregor, Burns Timothy F, Bergsland Emily K, Munster Pamela N, Ashworth Alan, LoRusso Patricia, Aggarwal Rahul R
Abstract excerpt
We sought to evaluate the efficacy of WEE1 inhibitor adavosertib in patients with solid tumor malignancies (cohort A) and clear cell renal cell carcinoma (ccRCC; cohort B). NCT03284385 was a parallel cohort, Simon two-stage, phase II study of adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle) in patients with solid tumor malignancies harboring a pathogenic SETD2 mutation. The primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.